Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.

LogiPharma Europe 2025: Three Ways to Turn Sustainability Pledges Into Progress

Articles

The program measures a company’s air cargo supply chain efforts when it comes to quality, safety, and compliance.

IATA CEIV Celebrates a Decade of Enhancing Air Cargo Efficiency 

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the company’s operations, particularly in terms of cost and supply chain management in the US market.

Analyzing Tariffs’ Effect on the Biopharmaceutical Supply Chain

Pharma Pulse 4/23/25: Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation, Trump Assessing Slashing US Drug Prices to International Levels

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares insights on how sustainability has evolved from a compliance requirement to a key business strategy, driving operational efficiencies, innovation, and long-term growth.

LogiPharma Europe 2025: Driving Business Success Through Sustainability

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

Reducing Polypharmacy in Older Adults

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

The Impact of Pharma Tariffs on Drug Shortages

Pharma Pulse 4/22/25: FDA Moves to Block Biopharma Employees From Serving on Advisory Committees, FDA Cuts Outlined in Draft HHS Budget

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies. 

Thermo Fisher Scientific Unveils Advanced Therapies Collaboration Center 

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, comments on the steps needed to achieve Drug Supply Chain Security Act compliance.

Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs